Please login to the form below

Not currently logged in
Email:
Password:

T-Vec

This page shows the latest T-Vec news and features for those working in and with pharma, biotech and healthcare.

Vyriad inks immunotherapy alliance with Merck/Pfizer

Vyriad inks immunotherapy alliance with Merck/Pfizer

an inflammatory reaction in the tumours, while avelumab take the brake off a T-cell mediated immune response in a double-whammy against the cancer, according to Vyriad’s chief executive ... The first and so far only therapy of this type to reach the

Latest news

  • Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

    This form of immuno-oncology has been spearheaded by Amgen, whose Imlygic (talimogene laherparepvec or T-Vec) was approved by the FDA last year, although it was not the first oncolytic

  • Amgen gets FDA nod for virus-based melanoma therapy Amgen gets FDA nod for virus-based melanoma therapy

    Imlygic (talimogene laherparepvec or T-Vec) is a genetically modified live Herpes simplex virus that is designed to infect and destroy melanoma lesions in the skin and lymph nodes that cannot

  • Amgen’s immuno-oncology drug scores in skin cancer Amgen’s immuno-oncology drug scores in skin cancer

    Talimogene Laherparepvec (or T-Vec), which works as an investigational oncolytic immunotherapy, was compared to those who received granulocyte-macrophage colony-stimulating factor (GM-CSF). ... Amgen is already conducting trials of T-Vec alongside

  • FDA panel backs Amgen's T-Vec for melanoma FDA panel backs Amgen's T-Vec for melanoma

    FDA panel backs Amgen's T-Vec for melanoma. Approved by a panel of 22 to one despite questions on its impact on survival. ... Amgen is already conducting trials of T-Vec alongside Merck's Keytruda (pembrolizumab).

  • Amgen banking on three launches in 2015 Amgen banking on three launches in 2015

    year. These are evolocumab for high cholesterol, heart failure drug Corlaner (ivabradine) and talimogene laherparepvec (T-VEC) for melanoma. ... Despite the upbeat comments, Amgen did reveal that Corlaner and T-VEC have both been delayed by requests for

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics